Abstracts tagged "interferon"

Abstract Number: 1708 • ACR Convergence 2023
In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity
Yan Du¹, Evan Hsu², Kailey Brodeur³, Meng Liu⁴, Mindy Lo⁵, Craig Platt³ and Pui Lee⁵, ¹Harvard medical school, Boston, MA, ²Wesleyan University, Newton, MA, ³Boston Children's Hospital, Boston, MA, ⁴Southern Medical University, Boston, MA, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic autoimmunity can be driven by monogenic or polygenic risk variants. We aimed to characterize the genetic basis of disease in a family with…
Abstract Number: 0093 • ACR Convergence 2023
Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients
Ye Cao¹, Takanori Sasaki², Richard Ainsworth³, Kim Taylor⁴, Nunzio Bottini⁵, Mehreen Elahee⁶, Edy Kim⁷, Francesco Boin³ and Deepak Rao⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, CA, ⁶University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…
Abstract Number: 0910 • ACR Convergence 2023
17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Kathryn Sullivan, Yong Wang, Winn Chatham, John Mountz and Hui-chen Hsu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…
Abstract Number: 1922 • ACR Convergence 2023
Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol
Charline Vauchy¹, Maxime Desmarets¹, Paul Bastard², Anne Puel², Pascale Richard³, Jean Laurent Casanova², Pierre Tiberghien³, Eric Toussirot⁴ and Francois Aubin⁵, ¹INSERM CIC-1431, Besançon, France, ²IHU Imagine, AP-HP Necker, Paris, France, ³Etablissement Français du Sang, St. Denis, France, ⁴University Hospital of Besancon, Besançon, France, ⁵Dermatology, University Hospital of Besancon, Besançon, France
Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Zoha Faheem¹, Giselle Boukhaled², Kieran Manion¹, Carolina Munoz-Grajales³, Carol Nassar¹, Michael Kim¹, Dafna Gladman⁴, Murray Urowitz⁵, Zahi Touma⁶, David Brooks² and Joan Wither⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
Abstract Number: 1963 • ACR Convergence 2023
Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis
Rita Spathis, Sabrina Narvesen, Deeva Robles Kuriplach, Karen Huang, Teja Sundar, Daniel Shulman, Elizabeth Bagley, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the interferon (IFN) pathway plays a major role in the pathophysiology of autoimmune myositis. Upregulation of type 1 IFN stimulated genes (an…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Ji Won Yang¹, Kun Hee Lee², Jin Seok Woo², Ha Yeon Jeong², JeongWon Choi², Eui-Jong Kwon¹, Mi-La Cho² and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
Abstract Number: 2044 • ACR Convergence 2023
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Alhanouf Alsaleem, Sulaiman Al-Mayouf and Shahad Alansari, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…
Abstract Number: 0574 • ACR Convergence 2023
Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
Kanwal Zahid Siddiqi¹, Amanda Hempel Zinglersen², Katrine Kjær Iversen¹ and Søren Jacobsen², ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Department of Rheumatology 4242, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark, ²Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 0598 • ACR Convergence 2023
Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Richard Furie¹, Victoria Werth², Eric Milliman³, Kyle Ferber³, Fergal Casey³, Roland Brown³, Denitza Raitcheva³, Jad Zoghbi³, Danielle Graham³, George Kong³, Youmna Lahoud³, Nathalie Franchimont⁴ and Catherine Barbey⁵, ¹Northwell Health, Manhasset, NY, ²University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³Biogen, Cambridge, MA, ⁴Former employee of Biogen, Cambridge, MA, ⁵Biogen, Baar, Switzerland
Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
Abstract Number: 1240 • ACR Convergence 2023
Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash
Ilaria Maccora¹, Patricia Vega-Fernandez², Kimberly Risma³ and Grant Schulert⁴, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, ³Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…

« Previous Page
1
…
8
9
10
11
12
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].